Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Chronic organ failure in adult sickle cell disease.

Vichinsky E.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):435-439. doi: 10.1182/asheducation-2017.1.435. Review.

PMID:
29222290
2.

The glomerulopathy of sickle cell disease.

Ataga KI, Derebail VK, Archer DR.

Am J Hematol. 2014 Sep;89(9):907-14. doi: 10.1002/ajh.23762. Epub 2014 Jun 19. Review.

3.

Intravenous infusion of haptoglobin for the prevention of adverse clinical outcome in Sickle Cell Disease.

Quimby KR, Hambleton IR, Landis RC.

Med Hypotheses. 2015 Oct;85(4):424-32. doi: 10.1016/j.mehy.2015.06.023. Epub 2015 Jun 29.

PMID:
26141635
4.

Aldosterone receptor antagonists: current perspectives and therapies.

Guichard JL, Clark D 3rd, Calhoun DA, Ahmed MI.

Vasc Health Risk Manag. 2013;9:321-31. doi: 10.2147/VHRM.S33759. Epub 2013 Jun 24. Review.

5.

Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.

Hsu TW, Liu JS, Hung SC, Kuo KL, Chang YK, Chen YC, Hsu CC, Tarng DC.

JAMA Intern Med. 2014 Mar;174(3):347-54. doi: 10.1001/jamainternmed.2013.12700.

PMID:
24343093
6.

[Programs for continuing medical education: B session; 6. Metabolic syndrome and chronic kidney disease].

Itoh H.

Nihon Naika Gakkai Zasshi. 2014 Mar 10;103(3):710-6. Review. Japanese. No abstract available.

PMID:
24796141
7.

Arterial hypertension and proteinuria in pediatric chronic kidney disease.

Simonetti GD, Bucher BS, Tschumi S, Lava SA, Bianchetti MG.

Minerva Pediatr. 2012 Apr;64(2):171-82. Review.

PMID:
22495191
8.

Angiotensin-converting enzyme inhibitor or Angiotensin receptor blocker use and renal outcomes-reply.

Hsu CC, Liu JS, Tarng DC.

JAMA Intern Med. 2014 Oct;174(10):1706-7. doi: 10.1001/jamainternmed.2014.1578. No abstract available.

PMID:
25285739
9.

Interventions for chronic kidney disease in people with sickle cell disease.

Roy NB, Fortin PM, Bull KR, Doree C, Trivella M, Hopewell S, Estcourt LJ.

Cochrane Database Syst Rev. 2017 Jul 3;7:CD012380. doi: 10.1002/14651858.CD012380.pub2. Review.

10.

Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials.

Xie X, Liu Y, Perkovic V, Li X, Ninomiya T, Hou W, Zhao N, Liu L, Lv J, Zhang H, Wang H.

Am J Kidney Dis. 2016 May;67(5):728-41. doi: 10.1053/j.ajkd.2015.10.011. Epub 2015 Nov 18.

PMID:
26597926
11.

An ACE in the hole for patients with advanced chronic kidney disease?

Park M, Hsu CY.

JAMA Intern Med. 2014 Mar;174(3):355-6. doi: 10.1001/jamainternmed.2013.12176. No abstract available.

PMID:
24342932
12.

Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use and renal outcomes: prevalent user designs may overestimate benefit.

Tomlinson L, Smeeth L.

JAMA Intern Med. 2014 Oct;174(10):1706. doi: 10.1001/jamainternmed.2014.1585. No abstract available.

13.

A mechanism for mineralocortcoid participation in renal disease and heart failure.

Re RN.

J Am Soc Hypertens. 2015 Aug;9(8):586-91. doi: 10.1016/j.jash.2015.05.002. Epub 2015 May 15. Review.

PMID:
26101172
14.

Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study.

Edner M, Benson L, Dahlström U, Lund LH.

Eur Heart J. 2015 Sep 7;36(34):2318-26. doi: 10.1093/eurheartj/ehv268. Epub 2015 Jun 11.

PMID:
26069212
15.

Development of albuminuria and enhancement of oxidative stress during chronic renin-angiotensin system suppression.

Ruiz-Hurtado G, Condezo-Hoyos L, Pulido-Olmo H, Aranguez I, Del Carmen Gónzalez M, Arribas S, Cerezo C, Segura J, Praga M, Fernández-Alfonso MS, Ruilope LM.

J Hypertens. 2014 Oct;32(10):2082-91; discussion 2091. doi: 10.1097/HJH.0000000000000292.

PMID:
25033166
16.

Angiotensin-converting enzyme inhibitors and receptor blockers in heart failure and chronic kidney disease - Demystifying controversies.

Muneer K, Nair A.

Indian Heart J. 2017 May - Jun;69(3):371-374. doi: 10.1016/j.ihj.2016.08.007. Epub 2016 Sep 8. Review.

17.

Effect of calcium channels blockers and inhibitors of the renin-angiotensin system on renal outcomes and mortality in patients suffering from chronic kidney disease: systematic review and meta-analysis.

Zhao HJ, Li Y, Liu SM, Sun XG, Li M, Hao Y, Cui LQ, Wang AH.

Ren Fail. 2016 Jul;38(6):849-56. doi: 10.3109/0886022X.2016.1165065. Epub 2016 Apr 7. Review.

PMID:
27055479
18.

Effects of direct renin inhibition versus angiotensin II receptor blockade on angiotensin profiles in non-diabetic chronic kidney disease.

Antlanger M, Bernhofer S, Kovarik JJ, Kopecky C, Kaltenecker CC, Domenig O, Poglitsch M, Säemann MD.

Ann Med. 2017 Sep;49(6):525-533. doi: 10.1080/07853890.2017.1313447. Epub 2017 Apr 17.

PMID:
28358246
19.

Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease.

Ahmed A, Fonarow GC, Zhang Y, Sanders PW, Allman RM, Arnett DK, Feller MA, Love TE, Aban IB, Levesque R, Ekundayo OJ, Dell'Italia LJ, Bakris GL, Rich MW.

Am J Med. 2012 Apr;125(4):399-410. doi: 10.1016/j.amjmed.2011.10.013. Epub 2012 Feb 7.

20.

Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: A clinical practice guideline from the American College of Physicians.

Qaseem A, Hopkins RH Jr, Sweet DE, Starkey M, Shekelle P; Clinical Guidelines Committee of the American College of Physicians.

Ann Intern Med. 2013 Dec 17;159(12):835-47.

PMID:
24145991

Supplemental Content

Support Center